GLP-1 weight loss drugs and muscle health in obesity
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study looks at how GLP-1 receptor agonist drugs (used for weight loss) affect muscle mass and strength in people with obesity who do not have diabetes. It may help understand if these medications impact muscle health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are obese (body mass index above 30)
- You are currently taking a GLP-1 weight loss drug
- You do not have diabetes
- You have no major hearing, speech, or thinking problems
- You are not being treated for major depression and do not take antidepressants
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how GLP-1 receptor agonist medications (like liraglutide or semaglutide) affect bone health in adolescents and young adults with obesity. It aims to understand if these weight loss drugs have any impact on bone density and metabolism.
This study looks at whether exercise can help prevent muscle loss in people taking GLP-1 medications (like Wegovy, Ozempic, or Mounjaro) for weight loss. It may help you keep your muscles strong while you lose weight.
This trial tests whether adding resistance exercise and extra protein can help you keep your muscle while taking weight loss medications like semaglutide or tirzepatide. It is for people with a BMI of 27 or higher who are not already exercising regularly.
This trial tests a weight-loss medication (GLP-1 receptor agonist) combined with dietary protein to see if it helps protect muscle while losing fat. It is for adults with obesity who are not taking certain other medications or supplements.
This trial tests whether combining a GLP-1 medication (a type of diabetes drug that also helps with weight loss) with an exercise program can improve physical function in people with obesity. If you are obese and have trouble with daily activities, this study may help you become more mobile and healthier.
This trial tests a new medicine, (S)-pindolol benzoate, given along with semaglutide (Ozempic/Wegovy). The goal is to see if it helps people lose mostly fat instead of muscle while on a weight loss program.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.